ABT vs DXCM Stock Comparison: AI Score, Valuation, Performance and Upside
Abbott and Dexcom both compete in continuous glucose monitoring, but Abbott operates this business as part of a much larger, diversified healthcare conglomerate spanning devices, diagnostics, nutrition, and pharmaceuticals, while Dexcom operates as a pure-play continuous glucose monitoring specialist.
Abbott offers diversified exposure to continuous glucose monitoring growth alongside a broad, stable healthcare portfolio, while Dexcom offers a concentrated, pure-play bet on continuous glucose monitoring category growth. Consider whether you prefer Abbott's diversified stability or Dexcom's focused CGM growth exposure.
DXCM holds the edge across 3 of 5 key metrics in this comparison. DXCM has delivered stronger 1-year price return (+45.59% vs -10.89%), though ABT has the better forward P/E setup (16.81x vs 29.07x for DXCM). DXCM leads on both revenue growth (13.10%) and operating margin (24.33%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABT (+17.96%) than for DXCM (+3.63%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want diversified exposure across medical devices, diagnostics, nutrition, and pharmaceuticals
- Value continuous glucose monitoring growth as one contributor within a broader, stable portfolio
- Believe diversification provides resilience against downturns in any individual segment
- Prefer a diversified conglomerate structure over a concentrated pure-play investment
- Want concentrated, pure-play exposure to continuous glucose monitoring category growth
- Believe international expansion provides a substantial incremental growth runway
- Value the focused research and development investment possible with a single-category business
- Are comfortable with revenue concentration risk tied to one product category
| Metric | ABT | DXCM |
|---|---|---|
| AI scorei | 51.8 | 52.3 |
| AI ranki | #451 | #250 |
| Latest closei | $110.16 | $84.76 |
| 1M returni | +12.98% | -0.70% |
| 3M returni | +2.84% | -2.92% |
| 6M returni | +25.84% | +41.17% |
| 1Y returni | -10.89% | +45.59% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABT | DXCM |
|---|---|---|
| 1Y ago | $8.9K (-11.0%) started 2025-11-03 | $14.03K (+40.3%) started 2025-11-03 |
| 5Y ago | $9.79K (-2.1%) started 2021-11-03 | $5.47K (-45.3%) started 2021-11-03 |
| 10Y ago | $39.57K (+295.7%) started 2016-11-03 | $56.43K (+464.3%) started 2016-11-03 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABT | DXCM |
|---|---|---|
| Market capi | $176.41B | $34.27B |
| Trailing P/Ei | 32.99 | 35.90 |
| Forward P/Ei | 16.81 | 29.07 |
| Price/Salesi | 5.49 | 8.19 |
| EV/Revenuei | 4.38 | 6.79 |
| Analyst targeti | $120.26 | $94.12 |
| Target upsidei | +17.96% | +3.63% |
| Metric | ABT | DXCM |
|---|---|---|
| Revenue growthi | 13.00% | 13.10% |
| Earnings growthi | -47.50% | 43.60% |
| EPS growthi | -47.50% | +43.60% |
| FCF margini | +15.48% | +20.55% |
| Operating margini | 14.71% | 24.33% |
| Profit margini | 11.65% | 20.12% |
| ROIC proxyi | 10.58% | 38.49% |
| Return on equityi | 10.58% | 38.49% |
| Dividend yieldi | 2.47% | N/A |
| Payout ratioi | 78.71% | 0.00% |
| Dividend growth streaki | No increase yet | N/A |
| Betai | 0.59 | 1.41 |
| Debt/equityi | 63.21 | 53.35 |
| Current ratioi | 1.38 | 1.73 |
| Quick ratioi | 0.80 | 1.37 |
Over the past year, ABT and DXCM have moved weakly in the same direction (correlation of 0.33), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABT | DXCM |
|---|---|---|---|
| 1Y | Growthi | -11.05% | +40.26% |
| CAGRi | -11.08% | +40.42% | |
| Volatilityi | 27.92% | 37.79% | |
| Sharpe ratioi | -0.45 | 0.97 | |
| Sortino ratioi | -0.63 | 1.58 | |
| Max drawdowni | 36.78% | 22.61% | |
| Current drawdowni | 15.64% | 8.21% | |
| Avg drawdowni | 18.28% | 6.51% | |
| Ulcer Indexi | 20.85% | 8.66% | |
| Max daily dropi | 10.04% | 6.39% | |
| Max wkly dropi | 13.11% | 10.71% | |
| 5Y | Growthi | -8.56% | -45.29% |
| CAGRi | -1.77% | -11.37% | |
| Volatilityi | 23.24% | 47.31% | |
| Sharpe ratioi | -0.15 | -0.10 | |
| Sortino ratioi | -0.22 | -0.14 | |
| Max drawdowni | 40.85% | 66.32% | |
| Current drawdowni | 21.07% | 47.94% | |
| Avg drawdowni | 18.13% | 41.72% | |
| Ulcer Indexi | 20.25% | 44.23% | |
| Max daily dropi | 10.04% | 40.66% | |
| Max wkly dropi | 13.11% | 42.68% | |
| 10Y | Growthi | +235.01% | +464.31% |
| CAGRi | +12.85% | +18.90% | |
| Volatilityi | 24.06% | 48.41% | |
| Sharpe ratioi | 0.44 | 0.51 | |
| Sortino ratioi | 0.63 | 0.74 | |
| Max drawdowni | 40.85% | 66.32% | |
| Current drawdowni | 21.07% | 47.94% | |
| Avg drawdowni | 10.99% | 27.05% | |
| Ulcer Indexi | 14.79% | 33.38% | |
| Max daily dropi | 10.04% | 40.66% | |
| Max wkly dropi | 16.72% | 42.68% |
| Category | ABT | DXCM |
|---|---|---|
| Company | Abbott Laboratories | DexCom, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | A diversified healthcare company operating across medical devices, diagnostics, nutrition, and established pharmaceuticals, including a continuous glucose monitoring business alongside a broad range of other healthcare products. | A medical device company specializing in continuous glucose monitoring systems for people with diabetes, providing sensor-based technology that tracks glucose levels in real time. |
| Investor focus | Continuous glucose monitoring segment growth, diagnostics and medical device segment trends, and overall diversified portfolio performance across all four business segments. | New sensor and system generation adoption, international market expansion, and revenue growth trajectory within the competitive continuous glucose monitoring category. |
- Highly diversified business across medical devices, diagnostics, nutrition, and pharmaceuticals reduces reliance on any single product category
- Continuous glucose monitoring business has grown into a substantial, high-growth contributor within the broader device portfolio
- Global scale and diversified revenue base provide resilience against downturns in any individual segment
- Pure-play focus on continuous glucose monitoring allows concentrated research and development investment in a single high-growth category
- Established brand recognition and clinical relationships within the diabetes care community support customer loyalty
- International expansion opportunities provide a substantial incremental growth runway beyond core developed markets
- Diversified conglomerate structure can make it harder for investors to isolate the value of specific high-growth segments like CGM
- Nutrition and diagnostics segments have historically grown more slowly than the medical device business
- Competitive dynamics in continuous glucose monitoring include well-resourced specialized competitors
- Revenue concentration entirely within continuous glucose monitoring creates exposure to competitive and reimbursement dynamics in that single category
- Competitive pressure from other well-resourced continuous glucose monitoring providers can affect pricing and market share
- Growth rate deceleration from earlier periods has required reliance on new product generations and international expansion for reacceleration
Compare more than two at a time
This page is a fixed writeup on ABT and DXCM. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside ABT and DXCM, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.